Shree Ganesh Remedies Ltd. Share Price

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Shree Ganesh Remedies has informed that the Board of Directors of the Company at its meeting held on today, Thursday, May 14, 2026 have considered and approved following: 1. Audited Financial Results (Standalone and Consolidated) of the company for the quarter and the financial year ended on March 31, 2026, along with the reports of Auditors thereon pursuant to Regulation 33 of SEBI LODR Regulations. Copy of the said Financial Results (Standalone and Consolidated) and Auditors Report is enclosed. Pursuant to Regulation 33 of SEBI LODR Regulations, it has declared that the statutory auditors have issued (Standalone and Consolidated) Audit Reports with unmodified opinion on the financial results of the Company for the year ended March 31, 2026; 2. Re-appointment of S N D K & Associates LLP, Chartered Accountants (Firm Registration No: W100060) as an Internal Auditors of the Company for the FY 2026-27. Details as required under Regulation 30 of the SEBI Listing Regulations read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762 /2026 dated January 30, 2026 are given as Annexure ‘A’. The Board of Directors Meeting commenced at 03:30 pm and concluded at 04:10 pm.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III thereto, AstraZeneca Pharma India has informed  that, Bhavana Agrawal, Executive Director and Chief Financial Officer (‘CFO’) has communicated her resignation from the position of CFO (Key Managerial Personnel) of the Company with effect from the close of business hours on August 31, 2026, pursuant to her appointment to a regional role within the AstraZeneca Group. A copy of the resignation letter is enclosed as Annexure – A. Further, the details as required under the SEBI Master Circular SEBI/HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure – B.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS® (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, Lupin has informed that Lupin Inc. U.S.A., wholly owned subsidiary of the Company, has entered into a licensing agreement to grant an exclusive perpetual license for two of its oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), to Kaveri Therapeutics, Inc. U.S.A. (‘Kaveri’), in exchange for an 82.2% equity stake (Common Shares) in Kaveri. The details required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI Master Circular dated January 30, 2026 (reference no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026), along with other applicable circulars, are set out in Annexure I. A press release regarding this arrangement is enclosed.

The above information is a part of company’s filings submitted to BSE.

A decrease in the sales to Rs. 558.26 millions was observed for the quarter ended June 2026. The sales stood at Rs. 663.25 millions during the similar quarter previous year.Good  Net Profit growth of 40.16% reported above the corresponding previous quarter figure of Rs. 42.33 millions to Rs. 59.33 millioins.OP of the company witnessed a marginal growth to 120.23 millions from 104.83 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	558.26	663.25	-15.83	558.26	663.25	-15.83	2254.30	2202.00	2.38
Other Income	18.67	29.75	-37.24	18.67	29.75	-37.24	111.43	61.92	79.96
PBIDT	120.23	104.83	14.69	120.23	104.83	14.69	396.87	376.08	5.53
Interest	16.01	27.88	-42.58	16.01	27.88	-42.58	118.07	47.56	148.25
PBDT	104.22	76.95	35.44	104.22	76.95	35.44	278.80	282.82	-1.42
Depreciation	24.85	20.38	21.93	24.85	20.38	21.93	96.69	74.42	29.92
PBT	79.37	56.57	40.30	79.37	56.57	40.30	182.11	208.40	-12.62
TAX	20.04	14.24	40.73	20.04	14.24	40.73	38.77	54.08	-28.31
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	59.33	42.33	40.16	59.33	42.33	40.16	143.34	154.32	-7.12
Equity	110.86	100.95	9.82	110.86	100.95	9.82	101.37	100.95	0.42
PBIDTM(%)	21.54	15.81	36.26	21.54	15.81	36.26	17.61	17.08	3.08